BIOX Specialist Joins Biomarker-based Diagnostics Group

Beogenomics, a specialised software developer in Bioinformatics and Artificial Intelligence (BIOX) has been acquired by APIS Assay Technologies Ltd, a company combining in vitro diagnostics (IVD) experience with integrated AI to develop biomarker-based diagnostic assays.

Start-up Beogenomics which has been developing both on-prem and secure cloud-based data analysis solutions to help design, build and run custom tailored genomics & proteomics pipelines, will be integrated into Manchester-based APIS, supporting the launch of a new BIOX Service Line that can deliver added value to customers.

Dr Joachim Schorr, CEO of APIS, said: “We are delighted to announce our acquisition of Beogenomics, which offers strong operational and cultural fits. We look forward to welcoming the talented team and working together to expand our BIOX capacity internally, and build out a new, discrete, and externally-facing service line.”

“With the addition of Beogenomics’ proven expertise in bioinformatics – APIS can more effectively capture the exciting opportunities presented in the bioinformatics space,” added Ian Kavanagh, COO of APIS.

Sir Richard Leese, Leader of Manchester City Council (MCC), said:  “Based on Manchester’s vision to establish a global genomics campus, the MCC investment into APIS already results in growth and very positive momentum as it brings together scientific expertise and cutting-edge technologies to develop novel biomarkers to help diagnose disease for patients in Greater Manchester and around the globe.”

The company’s structured R&D programme adopts a ‘portfolio model’ towards biomarker characterisation, linking the generated biomarker to data in relevant external datasets.

More information online